A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer

M. Lopez, A. Contegiacomo, P. Vici, C. Dello Ioio, L. Di Lauro, C. Pagliarulo, S. Carpano, D. Giannarelli, S. De Placido, S. Fazio, A. R. Bianco

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who recieved DX treatment the overall response rate was 46%, whereas it was 21% in 34 evaluable patients treated with IDA. This difference was statistically significant. In previously untreated patients the response rate with DX was 60% compared to 29% with IDA. Patients with prior chemotherapy had 29% response rate to DX in contrast to 12% with IDA. The median time to response, the median response duration, and the median time to progression were similar in both groups. The median survival of all patients was 20 months in DX arm and 14 months in IDA arm (95% confidence limits 16.69-23.31 and 10.77-17.23, respectively; P = 0.09). Both treatments produced equivalent incidence and severity of myelotoxicity. Gastrointestinal toxicity and alopecia were significantly lower in patients receiveing IDA. As for cardiotoxicity, four cases of congestive heart failure were recorded among patients treated with DX whereas no cases occurred in the IDA group. The results of this study indicate that, although DX remains the best single agent available in the treatment of breast cancer, IDA may have a role in selected patients with this disease.

Original languageEnglish
Pages (from-to)2431-2436
Number of pages6
JournalCancer
Volume64
Issue number12
DOIs
Publication statusPublished - 1989

Fingerprint

Idarubicin
Doxorubicin
Breast Neoplasms
Therapeutics
Alopecia
Heart Failure
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. / Lopez, M.; Contegiacomo, A.; Vici, P.; Dello Ioio, C.; Di Lauro, L.; Pagliarulo, C.; Carpano, S.; Giannarelli, D.; De Placido, S.; Fazio, S.; Bianco, A. R.

In: Cancer, Vol. 64, No. 12, 1989, p. 2431-2436.

Research output: Contribution to journalArticle

Lopez, M, Contegiacomo, A, Vici, P, Dello Ioio, C, Di Lauro, L, Pagliarulo, C, Carpano, S, Giannarelli, D, De Placido, S, Fazio, S & Bianco, AR 1989, 'A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer', Cancer, vol. 64, no. 12, pp. 2431-2436. https://doi.org/10.1002/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1
Lopez, M. ; Contegiacomo, A. ; Vici, P. ; Dello Ioio, C. ; Di Lauro, L. ; Pagliarulo, C. ; Carpano, S. ; Giannarelli, D. ; De Placido, S. ; Fazio, S. ; Bianco, A. R. / A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. In: Cancer. 1989 ; Vol. 64, No. 12. pp. 2431-2436.
@article{5d94581e17fa4558a43cc7b5448be304,
title = "A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer",
abstract = "Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who recieved DX treatment the overall response rate was 46{\%}, whereas it was 21{\%} in 34 evaluable patients treated with IDA. This difference was statistically significant. In previously untreated patients the response rate with DX was 60{\%} compared to 29{\%} with IDA. Patients with prior chemotherapy had 29{\%} response rate to DX in contrast to 12{\%} with IDA. The median time to response, the median response duration, and the median time to progression were similar in both groups. The median survival of all patients was 20 months in DX arm and 14 months in IDA arm (95{\%} confidence limits 16.69-23.31 and 10.77-17.23, respectively; P = 0.09). Both treatments produced equivalent incidence and severity of myelotoxicity. Gastrointestinal toxicity and alopecia were significantly lower in patients receiveing IDA. As for cardiotoxicity, four cases of congestive heart failure were recorded among patients treated with DX whereas no cases occurred in the IDA group. The results of this study indicate that, although DX remains the best single agent available in the treatment of breast cancer, IDA may have a role in selected patients with this disease.",
author = "M. Lopez and A. Contegiacomo and P. Vici and {Dello Ioio}, C. and {Di Lauro}, L. and C. Pagliarulo and S. Carpano and D. Giannarelli and {De Placido}, S. and S. Fazio and Bianco, {A. R.}",
year = "1989",
doi = "10.1002/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1",
language = "English",
volume = "64",
pages = "2431--2436",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer

AU - Lopez, M.

AU - Contegiacomo, A.

AU - Vici, P.

AU - Dello Ioio, C.

AU - Di Lauro, L.

AU - Pagliarulo, C.

AU - Carpano, S.

AU - Giannarelli, D.

AU - De Placido, S.

AU - Fazio, S.

AU - Bianco, A. R.

PY - 1989

Y1 - 1989

N2 - Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who recieved DX treatment the overall response rate was 46%, whereas it was 21% in 34 evaluable patients treated with IDA. This difference was statistically significant. In previously untreated patients the response rate with DX was 60% compared to 29% with IDA. Patients with prior chemotherapy had 29% response rate to DX in contrast to 12% with IDA. The median time to response, the median response duration, and the median time to progression were similar in both groups. The median survival of all patients was 20 months in DX arm and 14 months in IDA arm (95% confidence limits 16.69-23.31 and 10.77-17.23, respectively; P = 0.09). Both treatments produced equivalent incidence and severity of myelotoxicity. Gastrointestinal toxicity and alopecia were significantly lower in patients receiveing IDA. As for cardiotoxicity, four cases of congestive heart failure were recorded among patients treated with DX whereas no cases occurred in the IDA group. The results of this study indicate that, although DX remains the best single agent available in the treatment of breast cancer, IDA may have a role in selected patients with this disease.

AB - Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who recieved DX treatment the overall response rate was 46%, whereas it was 21% in 34 evaluable patients treated with IDA. This difference was statistically significant. In previously untreated patients the response rate with DX was 60% compared to 29% with IDA. Patients with prior chemotherapy had 29% response rate to DX in contrast to 12% with IDA. The median time to response, the median response duration, and the median time to progression were similar in both groups. The median survival of all patients was 20 months in DX arm and 14 months in IDA arm (95% confidence limits 16.69-23.31 and 10.77-17.23, respectively; P = 0.09). Both treatments produced equivalent incidence and severity of myelotoxicity. Gastrointestinal toxicity and alopecia were significantly lower in patients receiveing IDA. As for cardiotoxicity, four cases of congestive heart failure were recorded among patients treated with DX whereas no cases occurred in the IDA group. The results of this study indicate that, although DX remains the best single agent available in the treatment of breast cancer, IDA may have a role in selected patients with this disease.

UR - http://www.scopus.com/inward/record.url?scp=0024809997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024809997&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1

DO - 10.1002/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1

M3 - Article

VL - 64

SP - 2431

EP - 2436

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -